Amneal Pharmaceuticals (NASDAQ:AMRX) Receives Hold (C) Rating from Weiss Ratings

Key Points

• Amneal Pharmaceuticals has received a "hold (C)" rating from Weiss Ratings, while JPMorgan Chase & Co. upgraded its price target for the stock from $12.00 to $14.00, indicating an "overweight" rating.
• In recent trading, Amneal Pharmaceuticals' stock price increased by 1.2%, reaching $10.48, with a twelve-month high of $10.68.
• Insider transactions show that notable executives sold significant portions of their stock, with Director John Kiely selling 32,000 shares valued at over $295,000, indicating potential concerns regarding the company's stock performance.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report)'s stock had its "hold (c)" rating reissued by analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, JPMorgan Chase & Co. boosted their price target on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an "overweight" rating in a report on Tuesday, September 16th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Amneal Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $12.00.

Amneal Pharmaceuticals Stock Up 1.2%

Shares of Amneal Pharmaceuticals stock traded up $0.12 on Wednesday, reaching $10.48. 1,617,336 shares of the stock were exchanged, compared to its average volume of 1,686,226. Amneal Pharmaceuticals has a twelve month low of $6.68 and a twelve month high of $10.68. The firm has a market capitalization of $3.29 billion, a price-to-earnings ratio of 1,049.05 and a beta of 1.18. The business has a 50 day moving average price of $9.44 and a two-hundred day moving average price of $8.33.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Research analysts forecast that Amneal Pharmaceuticals will post 0.53 EPS for the current year.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director John Kiely sold 32,000 shares of the company's stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $9.23, for a total value of $295,360.00. Following the completion of the sale, the director directly owned 225,433 shares in the company, valued at $2,080,746.59. This represents a 12.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Nikita Shah sold 6,340 shares of the company's stock in a transaction on Monday, August 25th. The shares were sold at an average price of $9.50, for a total value of $60,230.00. Following the completion of the sale, the executive vice president owned 146,403 shares of the company's stock, valued at approximately $1,390,828.50. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 609,206 shares of company stock valued at $5,700,625 over the last ninety days. Company insiders own 17.45% of the company's stock.

Institutional Trading of Amneal Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC grew its holdings in Amneal Pharmaceuticals by 26.9% in the 1st quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company's stock valued at $162,000 after buying an additional 4,100 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Amneal Pharmaceuticals by 53.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company's stock valued at $508,000 after buying an additional 21,079 shares in the last quarter. California State Teachers Retirement System lifted its stake in shares of Amneal Pharmaceuticals by 10.3% in the 4th quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock valued at $1,043,000 after purchasing an additional 12,282 shares during the last quarter. Amalgamated Bank lifted its stake in shares of Amneal Pharmaceuticals by 33.0% in the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after purchasing an additional 1,367 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its stake in shares of Amneal Pharmaceuticals by 51.3% in the 1st quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company's stock valued at $21,759,000 after purchasing an additional 880,471 shares during the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.